George Bakris, MD, on the Renal Outcomes From the CREDENCE Trial
In this podcast, George Bakris, MD, from the University of Chicago, talks about the renal outcomes from the Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) trial. More at: www.consultant360.com/cardiology.